Zedira receives funding for the development of transglutaminase inhibitors
Advertisement
Zedira announced today that the BMBF will grant additional 1.5 million Euros funding to the company within the highly competitive SME-Innovative program over the next three years.
The aim of the project is for Zedira to develop small molecule tissue transglutaminase inhibitors that are orally bioavailable. Transglutaminase is considered to be a scientifically validated target in certain fibrotic diseases such as diabetic nephropathy. Kidney injury is one of the most severe complications of diabetes.